Matinas BioPharma Hlds

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Matinas BioPharma advances MAT2203, faces financial challenges, and extends cash runway

Matinas BioPharma's progress on MAT2203 and positive feedback position the company well in the infectious disease treatment market.
Financially, the company faces challenges with no revenue, high expenses, and a need to carefully manage cash reserves for sustained operations.
Opportunities lie in advancing MAT2203 towards Phase III trials, exploring new therapeutic areas, and extending cash runway for future growth.
Overall, Matinas BioPharma's focus on innovation and strategic partnerships sets the stage for potential growth and market leadership in infectious disease treatments.

Matinas BioPharma reports improved Q2 performance and advances key drug programs

Matinas BioPharma's Q2 2024 performance reflects improved cost management and financial stability, supported by a strengthened cash position and ongoing progress in key drug development programs.
While challenges persist in revenue generation and trial timelines, the company's strategic strengths in product pipeline expansion and innovation present opportunities for future growth and market success.
Overall, Matinas BioPharma's focus on advancing key drug candidates and addressing clinical needs in fungal infections positions the company for potential revenue growth and market leadership in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been terminated following notification from the prospective partner. As a result, Matinas has implemented an 80% workforce reduction effective immediately, eliminating 15 positions including three members of senior management, and has ceased all product development activities to conserve cash.

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Keith Kucinski – Chief Financial Officer Terri Matkovits – Chief Development Officer Conference Call Participants Scott Henry – Alliance Global Partners Joanne Lee – Maxim Group Operator Welcome to the Matinas BioPharma Second Quarter 2024 Financial Results Conference Call. Currently all participants are in a listen-only mode.

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas' Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S.

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.

Arqit Quantum Inc

Avino Silver & Gold Mines

BlackSky Technology

Hookipa Pharma Inc

Knightscope

Lilium BV

Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential.

Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Matinas BioPharma Hldgs (NYSEMKT: MTNB ) just reported results for the first quarter of 2024. Matinas BioPharma Hldgs reported earnings per share of -3 cents.

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners Operator Welcome, everyone, to the Matinas BioPharma First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript

Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 33,333,334 shares of common stock, at a combined offering price of $0.30 per share and accompanying warrant, pursuant to a registered direct offering. The warrants will have an exercise price of $0.35 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance.

Matinas BioPharma Prices $10 Million Registered Direct Offering

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces complete clinical response in three patients with serious invasive fusarium infection following treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. All three patients were enrolled in the Company's Compassionate/Expanded Use Access Program and were treated by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.

Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced that on March 21, 2024, the Company received written notification from the NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to the low selling price of its common stock as described in Section 1003(f)(v) of the NYSE American Company Guide due to shares of its common stock demonstrating sustained price improvement.

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript

PaxMedica Inc

NanoVibronix

Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.

Penny Stocks To Buy Now? 3 to Watch With Big News

Study results show reduction in tumor size comparable to IV docetaxel and no systemic toxicity Study results show reduction in tumor size comparable to IV docetaxel and no systemic toxicity

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Annovis Bio

Avalo Therapeutics

Tempest Therapeutics

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.

News for Matinas BioPharma Hlds Stock (MTNB)